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Abstract
Introduction Selective internal radiotherapy (SIRT) with yttrium-90 (Y-90) is an intra-arterial therapy for hepatic malignancy in
patients who are unsuitable for surgical resection. This treatment is considered palliative, although some patients can demonstrate
a response that is adequate to facilitate surgical resection with curative intent.
Methods All patients who underwent liver resection post SIRT were reviewed. Data gathered included patient demographics,
tumor type, surgical details, and post-operative outcomes.
Results Twelve patients underwent SIRT followed by liver resection (7 males and 5 females). Pathologies were hepatocellular
carcinoma (n = 5), metastatic colorectal cancer (n = 5), and neuroendocrine tumor (n = 2). Lesional response (size, volume, and
RECIST (response evaluation criteria in solid tumors)) was calculated and where appropriate functional liver remnant (FLR) is
presented. Mean FLR increase was 264cm3 (range − 123 to 909), and all cases demonstrated a partial response according to
RECIST with a mean largest lesion volume reduction of 475cm3 (range 14–1632). No post-SIRT complications were noted.
Hepatectomy occurred at a mean of 322 days from SIRT treatment. Ninety-day morbidity was 67% (n = 6), complications post-
surgery were analyzed according to the Clavien-Dindo classification scale; a total of 15 events occurred in 6 patients. Ninety-day
mortality of 11% (n = 1).
Conclusion In selected cases, liver resection is possible post SIRT. As this can represent a potentially curative option, it is
important to reconsider resection in the follow-up of patients undergoing SIRT. Post-operative complications are noted following
major and extended liver resection. Therefore, further studies are needed to improve patient selection.
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Introduction
Selective internal radiotherapy (SIRT) with yttrium-90 (Y90)
is an intra-arterial directed therapy for hepatic malignancy.
Small (20–60 μm) microspheres containing Y90, a beta
emitter with a mean penetration range of 2.5 mm and a half-
life of 64 h are infused into the target liver arteries in order to
treat the tumors [1, 2]. As hepatic tumors are mostly supplied
by the arterial system, the delivery of Y90-coated micro-
spheres into the liver arteries has a localized brachytherapy
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effect, while aiming to spare normal liver parenchyma which
is supplied by the portal venous system. There are two com-
mercially available forms of Y90 microspheres; Theraspheres
(BTG, London, UK) which produce glass-coated micro-
spheres and SIR-Spheres (Sirtex, Sydney, Australia) which
produce resin coated microspheres.
Most of the reported clinical evidence for SIRT is in the
context of metastatic colorectal cancer (mCRC), hepatocellular
carcinoma (HCC), and metastatic neuroendocrine tumors
(mNET) [2]. The role of SIRT in the management of other
hepatic malignancies is evolving [3]. For mCRC, data demon-
strates SIRT can improve progression-free survival in the liver,
although results on its influence on overall survival and quality
of life are evolving https://www.thelancet.com/journals/lanonc/
article/PIIS1470-2045(17)30457-6/fulltext [4–6]. In HCC,
SIRT may improve survival when compared with transarterial
chemoembolization (TACE) and have potentially similar over-
all survival compared with sorafenib, but with an improved side
effect profile [7, 8]. FormNET, SIRT has been associatedwith a
high response rate and improved survival [9].
Despite promising results, SIRT is considered a salvage
therapy. A small cohort of patients can however have a re-
sponse to SIRT which renders them potential candidates for
curative surgical resection [10, 11]. The experience with he-
patic resection post SIRT is limited with less than 100 pub-
lished cases. We retrospectively reviewed our experience with
this technique.
Materials and Methods
Between 2011 and 2017, 138 Y90 deliveries were given in
107 patients. All patients underwent multi-disciplinary dis-
cussion prior to consideration of SIRT and were deemed
surgically unresectable. Prior to administering SIRT, all
patients received a planning angiogram and technetium
99mTc macro aggregated albumin (T99mMAA) injection
with subsequent gamma camera scintigraphy or CT-
SPECT to detect shunting into the lungs or extrahepatic
uptake. Follow-up imaging was planned at three monthly
intervals post SIRT, but this did not occur in all patients. It
is important to emphasize that similar to a previous study,
SIRT was not intended a bridge to surgical resection at the
time of treatment [11].
On subsequent follow-up imaging, a patient had response
to SIRT whereby the surgical team thought surgical resection
would be possible, then these cases were rediscussed at the
multi-disciplinary tumor board. All patients who underwent
hepatic resection post SIRT were reviewed.
Following resection, the 90-day post-operative mortality
and morbidity were reviewed. In order to allow for compari-
son with a previous case series, morbidity was determined by
Clavien-Dindo [12].
Results
Patients
A total of 12 (7 males, 5 females) patients underwent hepatic
resection following SIRT, representing 11% of all SIRT cases.
All patients had a normal serum bilirubin (5.0 to 17.0mmol/L)
and had stopped chemotherapy at least 6 weeks prior to SIRT.
Outcomes for 3 patients of these patients are not included in
this review as one patient lacked follow up imaging data,
another had a confounding procedure (portal vein emboliza-
tion), and the third had a hemi hepatectomy with palliative
intent due to symptomatic carcinoid syndrome with neuroen-
docrine metastases. Cases performed with curative intent were
reviewed. A summary of case details is provided in Tables 1,
2, 3 and 4.
SIRT
Five patients underwent a single SIRT treatment while the
remaining 4 patients had two treatments (this included two
planned staged treatments and two repeat administrations).
Eight patients had unilobar SIRT, and 1 patient received
whole-liver SIRT. For the 2 patients who received a second
SIRT administration, this occurred due to significant residual
disease post initial SIRT, and following multi-disciplinary dis-
cussion, a second treatment was felt to be in the patients’ best
interests. No SIRT-related complication was seen. All lesions
demonstrated a partial response to SIRT with a mean largest
lesion volume reduction of 475 cm3 (range 14–1632). Where
functional liver remnant (FLR) was felt to be a contributory
reason to being unresectable, this was also calculated pre and
post SIRT with a mean increase in FLR increase of 264 cm3
(range − 123 to 909). One patient has a decrease in FLR (−
123 cm3) as they received a bilobar treatment where the FLR
was also exposed to SIRT. All patients who were initially
unresectable on multi-disciplinary review had a reduction in
lesion size and/or regression from critical vascular structures
and/or increase in the necessary FLR. Patients proceeded to
resection only after undergoing secondary multi-disciplinary
review after SIRT response.
Surgical Outcomes
Mean time from SIRT to resection was 322 days (range 195–
703) . Surg ica l p rocedures were ex tended r ight
hemihepatectomy (n = 5), right hepatectomy (n = 1), extended
left hepatectomy (n = 2), and right posterior sectionectomy
(n = 1). Two cases required resection and reconstruction of
the IVC. One case also underwent a metastasectomy at resec-
tion and another a roux-en-y hepaticojejunostomy. A R0 re-
section was achieved in 4 patients (44%).
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Table 1 Demographics
Patient Gender Diagnosis Tumor
volume
(cm3)
Pre-SIRT
FLR
SIRT treatment Post SIRT
tumor
volume
Post SIRT
FLR
Change in
FLR
1 F Metastatic colorectal 35 625 SIRTEX–right lobe 21 1096 + 275
2 F Metastatic
neuroendocrine
109 240 SIRTEX–right lobe and
segment 4 (staged)
41 420 + 180
3 M HCC 1150 656 SIRTEX–right lobe 136 819 + 163
4 M HCC 998 920 SIRTEX–left lobe 21 1126 + 206
5 F Metastatic colorectal 33 490 SIRTEX–right lobe 9 936 + 446
6 (Figure 1 and 2) M HCC 1695 560 TheraSpheres–two
treatments
right lobe/segment 4
63 1469 + 909
7 M HCC 508 1350 TheraSpheres–right lobe 306 1524 + 174
8 M Metastatic colorectal 22 347 SIRTEX–right lobe 5 493 + 146
9 F HCC (Fibrolamellar) 350 1250 TheraSpheres–bilobar
split treatment
20 1127 − 123*
Volumes calculated in cm3
Due to bilobar treatment, some of the SIRT dose is likely given to FLR resulting in reduction in overall FLR
Table 2 Surgical details
Patient SIRT to
resection
(days)
Surgery Margin
1 147 Extended right hemihepatectomy R0
2 703 Right hemihepatectomy and metastectomy ×3 and
right hemicolectomy
R1
3 195 Extended right hepatectomy R1
4 334 Left hemi hepatectomy R0
5 130 Extended right hepatectomy, caudae lobectomy,
and IVC reconstruction
R1
6 234 Extended right hemihepatectomy and roux-en-y
gastrojejunostomy (Figure 3)
R1
7 678 Right posterior sectionectomy (segment 6/7) and
cholecystectomy
R0
8 218 Extended right hemihepatectomy R1
9 256 Extended left hepatectomy with resection and
reconstruction of IVC
R0
Table 3 All Complications
related to hepatic resection post
SIRT
Classification (Clavien-Dindo) Event Number
I
II Pneumonia 2
Biliary Sepsis 2
IVC Thrombus 1
IIIa Bile Leak 4
Biliary sepsis requiring percutaneous decompression 1
IIIb Bilio-pleural fistula 1
Hepatic vein stenosis (stented) 1
IVa Respiratory failure 1
IVb Multi organ failure 1
V Death 1
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Median hospital stay was 16.5 days (range 6–79) with
one re-admission (11%). The 90-day morbidity rate was
67% (n = 6) with 15 complications occurring in 6 patients,
of which 10 complications were Clavien-Dindo grade 3 or
above (Table 3). Ninety-day mortality was 11% (n = 1)
where a patient died 79 days post procedure following a
complicated post-operative course with chest sepsis, bile
leak, hepatic vein stenosis (stented), and subsequent
multi-organ failure. No cases of post-hepatectomy liver
failure were seen.
At mean follow-up at 878 days [range 79-2156], three
patients died of which two developed radiographic progres-
sion, 5 patients remain alive and 1 was lost to follow up.
Discussion
With hepatic malignancy drawing its blood supply primarily
from the hepatic arterial system, the delivery of Y90 micro-
spheres into this circulation is theorized to have preferential
uptake in tumor cells rather than the normal liver tissue which
is supplied by the portal venous system. As a beta emitter, the
Y90 loaded microspheres have an effective radiotherapy
range of about 2 .5mm and induce tumor cell injury through
DNA damage [2]. Due to the short effective distance of the
microspheres and portal venous blood supply, normal hepatic
parenchyma should be relatively spared from the Y90 micro-
sphere’s radiotherapy effect [13].
Fig. 1 Contrast-enhanced CT of a male patient with a 14-cm HCC (or-
ange circle) with a tumor volume of 1695 cm3 and inadequate FLR
(560 cm3) for surgical resection
Fig. 2 Contrast-enhanced CT following two SIRT treatments. The tumor
had decreased in size to a volume of 63 cm3, and the FLR increased to
1469 cm3 rendering the patient suitable for surgical resection
Table 4 Surgical outcomes
Patient Length
of stay
Complication 90-Day re-
admission
Cause for re-
admission
1 79 (died) Hepatic vein stenosis (stented), biliary sepsis,
bile leak, pneumonia,
and multi-organ failure
NA
2 20 None No
3 6 None No
4 13 None No
5 30 Bile leak/collection No
6 79 Bile leak, sepsis, respiratory failure,
and bilio-pleural fistula
Yes Rigor with
displaced
biliary drain
7 10 Hospital acquired pneumonia No
8 11 Biliary sepsis No
9 67 Bile leak, IVC thrombus No
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Surgical resectability is determined by the ability to safely
achieve a surgical margin (R0) while preserving a residual ade-
quate liver volume ((FLR) future liver remnant), typically 25–
30% of a healthy liver, but can increase up to 40% in patients
with cirrhosis or after significant doses of chemotherapy [14]. If
the FLR is the limiting factor for resection but is tumor free,
portal vein embolization (PVE) can be considered to increase
FLR. In the context of PVE failure, or bilobar disease, associating
liver partition and portal vein ligation for staged hepatectomy
(ALPPS) has been suggested as an alternative, albeit more con-
troversial [15]. The disadvantage of both PVE andALPPS is that
while hepatic hypertrophy occurs, the initial disease process is
left to progress and can even be stimulated by the hypertrophy
process. Unilobar SIRT has the advantage of treating the liver
tumors, which can result in volume reduction of the diseased lobe
and contralateral lobe hypertrophy [16]. Furthermore, the hyper-
trophy occurs over an extended period of time, typically a num-
ber of months. This is reflected in the observed time from SIRT
to surgery time (mean 322 days). It is thought this slower hyper-
trophy (compared to PVE or ALPPS) provides a better liver
function per volume in the remnant liver. However, the degree
of contralateral hypertrophy is typically less than can be achieved
with PVE [17]. The precise mechanism for hypertrophy post
SIRT is not known, but is likely multifactorial due to changes
in portal venous hemodynamics and biochemical influences
[18–23]. Except one The R0 resection rate of 44% in this series
was despite the use of intraoperative ultrasound guiding clear
resection of all of macroscopic disease. Of note, the positive
margins identified after scrupulous histological examination
consisted of limited microscopic infiltrative areas in areas not
amenable to further surgical resection.
With its ability to both downstage disease and increase FLR,
surgical resection after SIRT has in recent years been per-
formed. Several case reports and small case series have
suggested it can be a technically feasible option in carefully
selected patients [24–29]. Only four larger series have also been
published with a total experience of n = 64 [10, 11, 30, 31]. In
two of these series, resection was an afterthought following
SIRT [10, 11] while Justinger et al. specifically selected mar-
ginally resectable cases and performed their surgical resections
at a shorter interval (approximately 2 months) following SIRT
[30]. Unless specifically intended at the time of SIRT, hepatic
resection following SIRT is rare, with published literature indi-
cating between 2 and 8% of patients receiving SIRT become
surgically resectable [10, 11]. More recent data from the
SIRFLOX trial has suggested that up to 13% of patients with
metastatic colorectal cancer can become resectable after SIRT
[32]. Further analysis the SIRFLOX imaging data post SIRT
has also suggested that more patients might become technically
resectable than initially thought [33].
Direct comparison of our data with other series is challeng-
ing due to the heterogeneous nature of the available informa-
tion. Several key themes however can be identified. Firstly,
surgical resection after SIRT is associated with an increased
morbidity compared to similar resections in patients who have
not undergone SIRT, most commonly a bile leak. Our 90-day
morbidity was in line with other studies ranging from 42 to 78%
[10, 11]. It is unclear whether this high morbidity is due to pre-
treatment with SIRT. Resections in cirrhotic patients with HCC
can have morbidities of greater than 50% [34]. However, in our
cohort, the majority of hepatic complications occurred in the
mCRC group. SIRT has been proposed to theoretically increase
surgical morbidity as it can induce sinusoidal obstruction. This
theory is purely based on the premise that sinusoidal obstruc-
tion can also be seen after oxaliplatin-based chemotherapy
which has been shown to increase operative morbidity [6, 35,
36]. SIRTcan also induce adhesion formation between the liver
and adjacent structures which has in one case required partial
diaphragmatic resection [6, 24]. One series with HCC patients
alone reported a much lower complication rate (16% Clavien-
Dindo grade III or above) [31].
The impact of tumor type on surgical morbidity and the safest
time for resection after SIRT are topics for further investigation.
What this data and that of related studies do highlight is that SIRT
should no longer be viewed only as a salvage therapy and pa-
tients’ cases should re-reviewed at multi-disciplinary tumor
boards for reconsideration of resection after SIRT. For patients
with inadequate FLRs, PVE remains the standard of care.
However, in circumstances where a tumor risks becoming
unresectable due to the tumor growth that can be induced by
PVE, SIRT may be a preferential treatment [37].
Conclusion
This study, while not changing suggested practice, contributes
to the existing limited evidence indicating that hepatic resection
Fig. 3 Contrast-enhanced CT following extended right hepatectomywith
roux-en-y hepaticojejunostomy
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after SIRT is technically possible albeit with a higher morbidity.
It is unclear whether the higher morbidity is due to pre-
treatment with SIRT. Patients demonstrating a response to
SIRT should be reconsidered for resection. Multi-disciplinary
tumor board decision making remains key to patient selection.
More research is needed to best identify candidates who may
benefit from surgical resection following SIRT.
Compliance with Ethical Standards
Conflict of Interest All authors declare that they have no conflict of
interest.
Ethical Approval All procedures performed in studies involving human
participants were in accordance with the ethical standards of the institu-
tional research committee and with the 1964 Helsinki declaration and its
later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants in-
cluded in the study.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Bhangoo MS, Karnani DR, Hein PN, Giap H, Knowles H, Issa C,
et al. Radioembolization with yttrium-90 microspheres for patients
with unresectable hepatocellular carcinoma. J Gastrointest Oncol.
2015 Oct;6(5):469–78.
2. Kennedy A. Radioembolization of hepatic tumors. J Gastrointest
Oncol. 2014;5(3):178–89.
3. Khajornjiraphan N, Thu NA, Chow PKH. Yttrium-90 micro-
spheres: a review of its emerging clinical indications. Liver
Cancer. 2015;4(1):6–15.
4. Townsend AR, Chong LC, Karapetis C, Price TJ. Selective internal
radiation therapy for liver metastases from colorectal cancer. Cancer
Treat Rev. 2016;50:148–54.
5. Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van
Hazel GA, et al. Selective internal radiation therapy (SIRT) with
yttrium-90 resin microspheres plus standard systemic chemothera-
py regimen of FOLFOX versus FOLFOX alone as first-line treat-
ment of non-resectable liver metastases from colorectal cancer: the
SIRFLOX study. BMC Cancer. 2014;1(14):897.
6. Garlipp B, Bruns CJ. The evidence for resection post-selective in-
ternal radiation therapy. Future Oncol. 2014;10(15s):49–52.
7. Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90
radioembolization versus chemoembolization for patients with hepato-
cellular carcinoma: a meta-analysis. Biosci Trends. 2015;9(5):289–98.
8. Vilgrain V, Abdel-RehimM, Sibert A, Ronot M, Lebtahi R, Castéra L,
et al. Radioembolisation with yttrium–90 microspheres versus sorafe-
nib for treatment of advanced hepatocellular carcinoma (SARAH):
study protocol for a randomised controlled trial. Trials. 2014;15:474.
9. Devcic Z, Rosenberg J, Braat AJA, Techasith T, Banerjee A, Sze
DY, et al. The efficacy of hepatic 90Y resin radioembolization for
metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med Off
Publ Soc Nucl Med. 2014;55(9):1404–10.
10. Henry LR, Hostetter RB, Ressler B, Bowser I, Yan M, Vaghefi H,
et al. Liver resection for metastatic disease after y90
radioembolization: a case series with long-term follow-up. Ann
Surg Oncol. 2015;22(2):467–74.
11. Wright GP, Marsh JW, Varma MK, Doherty MG, Bartlett DL,
ChungMH. Liver resection after selective internal radiation therapy
with yttrium-90 is safe and feasible: a bi-institutional analysis. Ann
Surg Oncol. 2017;24(4):906–13.
12. Dindo D, Demartines N, Clavien P-A. Classification of surgical
complications. Ann Surg. 2004;240(2):205–13.
13. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C.
Pathologic response and microdosimetry of (90)Y microspheres
in man: review of four explanted whole livers. Int J Radiat Oncol
Biol Phys. 2004;60(5):1552–63.
14. Rotellar F, Pardo F, Martínez-Ortega P. The safety of resection post-
selective internal radiation therapy. Future Oncol. 2014;10(15s):53–5.
15. Cai Y-L, Song P-P, TangW,ChengN-S. An updated systematic review
of the evolution of ALPPS and evaluation of its advantages and disad-
vantages in accordance with current evidence. Medicine (Baltimore)
[Internet]. 2016 Jun 17 [cited 2017 Jun 3];95(24). Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998492/
16. Manas DM. Hypertrophy in the contralateral lobe post-selective
internal radiation therapy. Future Oncol. 2014;10(15s):65–7.
17. Garlipp B, de Baere T, DammR, Irmscher R, van BuskirkM, Stübs
P, et al. Left-liver hypertrophy after therapeutic right-liver
radioembolization is substantial but less than after portal vein em-
bolization. Hepatol Baltim Md. 2014;59(5):1864–73.
18. Teo J-Y, Allen JC, Ng DC, Choo S-P, Tai DWM, Chang JPE, et al. A
systematic review of contralateral liver lobe hypertrophy after unilobar
selective internal radiation therapy with Y90. HPB. 2015;n/a-n/a.
19. Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai
V, et al. Fibrosis, portal hypertension, and hepatic volume changes
induced by intra-arterial radiotherapy with 90yttriummicrospheres.
Dig Dis Sci. 2008;53(9):2556–63.
20. Fernández-Ros N, Silva N, Bilbao JI, Iñarrairaegui M, Benito A,
D’Avola D, et al. Partial liver volume radioembolization induces
hypertrophy in the spared hemiliver and no major signs of portal
hypertension. HPB. 2014;16(3):243–9.
21. Kawai M, Naruse K, Komatsu S, Kobayashi S, Nagino M, Nimura
Y, et al. Mechanical stress-dependent secretion of interleukin 6 by
endothelial cells after portal vein embolization: clinical and exper-
imental studies. J Hepatol. 2002;37(2):240–6.
22. Hayashi H, Beppu T, Sugita H, Masuda T, Okabe H, Takamori H,
et al. Serum HGF and TGF-beta1 levels after right portal vein em-
bolization. Hepatol Res Off J Jpn Soc Hepatol. 2010;40(4):311–7.
23. Kusaka K, Imamura H, Tomiya T, Takayama T, Makuuchi M.
Expression of transforming growth factor-alpha and -beta in hepatic
lobes after hemihepatic portal vein embolization. Dig Dis Sci.
2006;51(8):1404–12.
24. Chua TC, Bester L, Akther J, Morris DL. Successful right hepatec-
tomy after four treatments of yttrium-90 microspheres (SIR-
spheres) and concomitant FOLFOX as bridging therapy to resection
of colorectal liver metastases. Anticancer Res. 2010;30(7):3005–7.
25. Neofytou K, Wasan H, Mudan S. Safety of redo hepatectomy for
colorectal liver metastases after selective interarterial radiation ther-
apy: a case report. Case Rep Surg [Internet] 2014 [cited 2017
Jun 1];2014. Available from: http://www.ncbi.nlm.nih.gov/pmc/
articles/PMC3971541/, 2014, 1, 5
26. Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K,
Price D, et al. Radioembolization of livermetastases from colorectal
cancer using yttrium-90 microspheres with concomitant systemic
oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin
Oncol Off J Am Soc Clin Oncol. 2007;25(9):1099–106.
J Gastrointest Canc
27. Sperling J, Justinger C, Schuld J, Ziemann C, Seidel R, Kollmar O.
Intrahepatic cholangiocarcinoma in a transplant liver–selective in-
ternal radiation therapy followed by right hemihepatectomy: report
of a case. World J Surg Oncol. 2014;12(1):198.
28. Wang LM, Jani AR, Hill EJ, Sharma RA. Anatomical basis and
histopathological changes resulting from selective internal radio-
therapy for liver metastases. J Clin Pathol. 2013;66(3):205–11.
29. Mafeld S, French J, Tiniakos D, Haugk B, Manas D, Littler P.
Fibrolamellar hepatocellular carcinoma: treatment with yttrium-90
and subsequent surgical resection. Cardiovasc Intervent Radiol.
2018;41(5):816–20.
30. Justinger C, Kouladouros K, Gärtner D, Tatsch K, Reimer P,
Rüdiger T, et al. Liver resection after selective internal radiotherapy
(SIRT): proof of concept, initial survival, and safety. J Surg Oncol.
2015;112(4):436–42.
31. Gabr A, AbouchalehN,Ali R, Baker T, Caicedo J, Katariya N, et al.
Outcomes of surgical resection after radioembolization for hepato-
cellular carcinoma. J Vasc Interv Radiol JVIR. 2018:27.
32. van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J,
Peeters M, et al. SIRFLOX: randomized phase III trial comparing
first-line mFOLFOX6 (plus or minus bevacizumab) versus
mFOLFOX6 (plus or minus bevacizumab) plus selective internal
radiation therapy in patients with metastatic colorectal cancer. J Clin
Oncol. 2016;34(15):1723–31.
33. Garlipp B, Gibbs P, Van Hazel GA, Jeyarajah R, Martin RCG,
Bruns CJ, et al. REsect: blinded assessment of amenability to
potentially curative treatment of previously unresectable colorectal
cancer liver metastases (CRC LM) after chemotherapy ±
RadioEmbolization (SIRT) in the randomized SIRFLOX trial. J
Clin Oncol. 2017;35(15_suppl):3532–2.
34. Wei AC, Tung-Ping Poon R, Fan S-T, Wong J. Risk factors for
perioperative morbidity and mortality after extended hepatectomy
for hepatocellular carcinoma. Br J Surg. 2003;90(1):33–41.
35. Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta
A, Viudez A, et al. Liver disease induced by radioembolization of
liver tumors: description and possible risk factors. Cancer.
2008;112(7):1538–46.
36. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM,
Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and
surgery versus surgery alone for resectable liver metastases from
colorectal cancer (EORTC intergroup trial 40983): a randomised
controlled trial. Lancet Lond Engl. 2008;371(9617):1007–16.
37. Cucchetti A, Cappelli A, Ercolani G, Mosconi C, Cescon M,
Golfieri R, et al. Selective internal radiation therapy (SIRT) as con-
version therapy for unresectable primary liver malignancies. Liver
Cancer. 2016;5(4):303–11.
Publisher’s Note Springer Nature remains neutral with regard to juris-
dictional claims in published maps and institutional affiliations.
J Gastrointest Canc
